RGNX vs BOLD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BOLD Captures Institutional Edge (3โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RGNX sits in BREAKDOWN (53rd %ile IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RGNX | BOLD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $474.8M | $56.2M | Larger Scale | RGNX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -69.2% | +0.0% | Higher Growth | BOLD |
| Operating Margin (TTM) Profitability | -120.4% | 0.0% | Higher Margin | BOLD |
| Net Profit Margin Profitability | -113.9% | 0.0% | Higher Margin | BOLD |
| Return on Equity (ROE) Capital Efficiency | -113.2% | -64.6% | Higher ROE | BOLD |
| 52-Week Range Position Momentum | 16% ($5โ$16) | 62% ($1โ$3) | Stronger Trend | BOLD |
| Beta / 30D Volatility Risk Regime | 1.65ฮฒ ยท 74% Vol | -0.08ฮฒ ยท 28% Vol | Lower Realized Risk | BOLD |
| Unified Institutional Score Composite Signal | 39.4 / 100 (SELL) | 36.8 / 100 (SELL) | Higher Composite | RGNX |